KMPHARMACEUTICAL Co.,Ltd. (KOSDAQ:225430)
South Korea · Delayed Price · Currency is KRW 621.00
-18.00 (-2.82%)
At close: Oct 29, 2025
KMPHARMACEUTICAL Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 14,015 | 14,475 | 17,770 | 15,631 | 22,705 | 22,928 | Upgrade |
Other Revenue | -0 | - | - | -0 | -0 | - | Upgrade |
| 14,015 | 14,475 | 17,770 | 15,631 | 22,705 | 22,928 | Upgrade | |
Revenue Growth (YoY) | -8.37% | -18.54% | 13.68% | -31.16% | -0.97% | 12.73% | Upgrade |
Cost of Revenue | 10,725 | 10,869 | 12,859 | 12,407 | 17,042 | 16,988 | Upgrade |
Gross Profit | 3,290 | 3,606 | 4,910 | 3,225 | 5,663 | 5,941 | Upgrade |
Selling, General & Admin | 4,687 | 4,865 | 4,976 | 3,219 | 3,948 | 4,537 | Upgrade |
Research & Development | 718.52 | 559.98 | 298.31 | 450.38 | 404.56 | 306.7 | Upgrade |
Amortization of Goodwill & Intangibles | 13.41 | 28.2 | 39.18 | 39.44 | 39.29 | 38.97 | Upgrade |
Other Operating Expenses | 81.71 | 76.4 | 59.75 | 59.04 | 59.54 | 138.13 | Upgrade |
Operating Expenses | 7,004 | 7,453 | 6,024 | 6,946 | 4,797 | 5,228 | Upgrade |
Operating Income | -3,714 | -3,848 | -1,113 | -3,722 | 866.14 | 712.32 | Upgrade |
Interest Expense | -597.05 | -582.34 | -613.68 | -384.49 | -173.49 | -495.16 | Upgrade |
Interest & Investment Income | 656.7 | 672.3 | 675.68 | 431.1 | 52.57 | 51.15 | Upgrade |
Currency Exchange Gain (Loss) | -7.27 | -1.59 | -6.09 | -12.15 | -15.66 | -15.23 | Upgrade |
Other Non Operating Income (Expenses) | -57.34 | -100.64 | 17.67 | -16.74 | -74.01 | 57.99 | Upgrade |
EBT Excluding Unusual Items | -3,718 | -3,860 | -1,040 | -3,704 | 655.55 | 311.07 | Upgrade |
Gain (Loss) on Sale of Investments | -474.7 | -389.25 | 74.79 | -61.63 | -674.13 | 15.99 | Upgrade |
Gain (Loss) on Sale of Assets | -0 | -0.21 | 10.42 | - | 6.56 | -4.66 | Upgrade |
Asset Writedown | - | - | -9.19 | -808.27 | -501.8 | - | Upgrade |
Pretax Income | -4,193 | -4,249 | -963.76 | -4,574 | -513.83 | 322.4 | Upgrade |
Income Tax Expense | 419.18 | 323.93 | 356.29 | -649.05 | 97.36 | -148.48 | Upgrade |
Net Income | -4,612 | -4,573 | -1,320 | -3,925 | -611.19 | 470.88 | Upgrade |
Net Income to Common | -4,612 | -4,573 | -1,320 | -3,925 | -611.19 | 470.88 | Upgrade |
Shares Outstanding (Basic) | 28 | 28 | 28 | 28 | 28 | 21 | Upgrade |
Shares Outstanding (Diluted) | 28 | 28 | 28 | 28 | 28 | 21 | Upgrade |
Shares Change (YoY) | -0.30% | -0.71% | 0.90% | 0.20% | 29.80% | 2.06% | Upgrade |
EPS (Basic) | -165.01 | -163.99 | -47.00 | -141.00 | -22.00 | 22.00 | Upgrade |
EPS (Diluted) | -165.01 | -163.99 | -47.00 | -141.00 | -22.00 | 22.00 | Upgrade |
Free Cash Flow | -2,584 | -2,401 | 1,333 | -151.02 | -97.92 | -2,828 | Upgrade |
Free Cash Flow Per Share | -92.45 | -86.09 | 47.48 | -5.42 | -3.52 | -132.12 | Upgrade |
Gross Margin | 23.48% | 24.91% | 27.63% | 20.63% | 24.94% | 25.91% | Upgrade |
Operating Margin | -26.50% | -26.58% | -6.26% | -23.81% | 3.82% | 3.11% | Upgrade |
Profit Margin | -32.91% | -31.60% | -7.43% | -25.11% | -2.69% | 2.05% | Upgrade |
Free Cash Flow Margin | -18.44% | -16.59% | 7.50% | -0.97% | -0.43% | -12.33% | Upgrade |
EBITDA | -2,520 | -2,513 | 255.73 | -2,263 | 2,308 | 1,854 | Upgrade |
EBITDA Margin | -17.98% | -17.36% | 1.44% | -14.47% | 10.17% | 8.09% | Upgrade |
D&A For EBITDA | 1,194 | 1,335 | 1,369 | 1,459 | 1,442 | 1,142 | Upgrade |
EBIT | -3,714 | -3,848 | -1,113 | -3,722 | 866.14 | 712.32 | Upgrade |
EBIT Margin | -26.50% | -26.58% | -6.26% | -23.81% | 3.82% | 3.11% | Upgrade |
Advertising Expenses | - | 990.45 | 470.11 | 577.67 | 700.87 | 640.13 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.